Literature DB >> 8074647

Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways.

S P Sreedharan1, D R Patel, M Xia, S Ichikawa, E J Goetzl.   

Abstract

Vasoactive intestinal peptide (VIP) is a potent neuropeptide mediator of central and peripheral nervous system function. A human VIP1 receptor (HVR) cDNA clone was previously obtained from HT29 intestinal epithelial cells and lung tissue. Stably-transfected human embryonic kidney 293 cells and chinese hamster ovary (CHO) cells expressing about 10(6) HVRs per cell that bind [125I]VIP with a Kd of 0.2-0.8 nM, and specifically recognized by anti-HVR antibodies, were established and characterized. VIP induced increases in intracellular cAMP levels ([cAMP]i) dose-dependently with an EC50 of 0.2 nM in 293 and CHO stable transfectants and concurrently evoked dose-dependent increases in intracellular calcium concentrations ([Ca2+]i), as determined by fluorescence-dye spectroscopy. Untransfected 293 and CHO cells showed minimal binding or intracellular effects of VIP; however, native VIP1 receptors of HT29 cells also increased [cAMP]i and [Ca2+]i in dose-dependent responses to VIP. Thus recombinant and native human VIP1 receptors both couple to two distinct signal transduction pathways within a single cell type.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074647     DOI: 10.1006/bbrc.1994.2160

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

Authors:  M Xia; S P Sreedharan; E J Goetzl
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

2.  Pituitary adenylate cyclase-activating polypeptide induces postsynaptically expressed potentiation in the intra-amygdala circuit.

Authors:  Jun-Hyeong Cho; Ko Zushida; Gleb P Shumyatsky; William A Carlezon; Edward G Meloni; Vadim Y Bolshakov
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

Review 3.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

4.  The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptor.

Authors:  N D Holliday; H M Cox
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

5.  Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene.

Authors:  S P Sreedharan; J X Huang; M C Cheung; E J Goetzl
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

Authors:  E J Goetzl; J K Voice; S Shen; G Dorsam; Y Kong; K M West; C F Morrison; A J Harmar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

7.  Neurotransmitter influence on human meibomian gland epithelial cells.

Authors:  Wendy R Kam; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-01       Impact factor: 4.799

8.  VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome.

Authors:  Shoko Nakayama; Taiji Yokote; Kichinosuke Kobayashi; Yuji Hirata; Tetsuya Hiraiwa; Izumi Komoto; Kazuho Miyakoshi; Yoshiko Yamakawa; Takayuki Takubo; Motomu Tsuji; Masayuki Imamura; Toshiaki Hanafusa
Journal:  Endocrine       Date:  2009-01-30       Impact factor: 3.633

Review 9.  Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.

Authors:  Jessica Lu; Sarah J Piper; Peishen Zhao; Laurence J Miller; Denise Wootten; Patrick M Sexton
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

10.  Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies.

Authors:  Ingrid Langer
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-30       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.